Loading...

Kiadis Pharma

DB:K3P
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
K3P
DB
€244M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Kiadis Pharma N.V., a clinical stage biopharmaceutical company, engages in the pharmaceutical development of cell-based immunotherapy products in the field of blood building system diseases. The last earnings update was 236 days ago. More info.


Add to Portfolio Compare Print
K3P Share Price and Events
7 Day Returns
-2.6%
DB:K3P
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
1.5%
DB:K3P
-7.4%
DE Biotechs
-5.6%
DE Market
K3P Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Kiadis Pharma (K3P) -2.6% 18.8% 8.1% 1.5% -5.2% -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • K3P outperformed the Biotechs industry which returned -7.4% over the past year.
  • K3P outperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
K3P
Industry
5yr Volatility vs Market
Related Companies

K3P Value

 Is Kiadis Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Kiadis Pharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Kiadis Pharma.

DB:K3P Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.6%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:K3P
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 25%) (12.73%))
1.396
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.4
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.396 * 5.96%)
8.55%

Discounted Cash Flow Calculation for DB:K3P using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Kiadis Pharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:K3P DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 8.55%)
2019 -26.18 Analyst x3 -24.12
2020 41.44 Analyst x1 35.17
2021 88.56 Analyst x1 69.24
2022 98.26 Analyst x1 70.77
2023 129.63 Analyst x1 86.01
2024 153.43 Est @ 18.35% 93.78
2025 173.24 Est @ 12.92% 97.55
2026 189.02 Est @ 9.11% 98.06
2027 201.21 Est @ 6.45% 96.15
2028 210.42 Est @ 4.58% 92.64
Present value of next 10 years cash flows €715.25
DB:K3P DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €210.42 × (1 + 0.23%) ÷ (8.55% – 0.23%)
€2,534.22
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €2,534.22 ÷ (1 + 8.55%)10
€1,115.68
DB:K3P Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €715.25 + €1,115.68
€1,830.93
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €1,830.93 / 24.34
€75.22
DB:K3P Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:K3P represents 1.01595x of ENXTAM:KDS
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.01595x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 75.22 x 1.01595
€76.42
Value per share (EUR) From above. €76.42
Current discount Discount to share price of €10.19
= -1 x (€10.19 - €76.42) / €76.42
86.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Kiadis Pharma is available for.
Intrinsic value
>50%
Share price is €10.19 vs Future cash flow value of €76.42
Current Discount Checks
For Kiadis Pharma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Kiadis Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Kiadis Pharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Kiadis Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Kiadis Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:K3P PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €-1.29
ENXTAM:KDS Share Price ** ENXTAM (2019-04-24) in EUR €10.03
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Kiadis Pharma.

DB:K3P PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTAM:KDS Share Price ÷ EPS (both in EUR)

= 10.03 ÷ -1.29

-7.76x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kiadis Pharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Kiadis Pharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Kiadis Pharma's expected growth come at a high price?
Raw Data
DB:K3P PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.76x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
60.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Kiadis Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Kiadis Pharma's assets?
Raw Data
DB:K3P PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €1.26
ENXTAM:KDS Share Price * ENXTAM (2019-04-24) in EUR €10.03
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:K3P PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTAM:KDS Share Price ÷ Book Value per Share (both in EUR)

= 10.03 ÷ 1.26

7.96x

* Primary Listing of Kiadis Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kiadis Pharma is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Kiadis Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Kiadis Pharma has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

K3P Future Performance

 How is Kiadis Pharma expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
60.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Kiadis Pharma expected to grow at an attractive rate?
  • Kiadis Pharma's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Kiadis Pharma's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Kiadis Pharma's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:K3P Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:K3P Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 60.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:K3P Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:K3P Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 451 204 1
2022-12-31 336 1
2021-12-31 220 1
2020-12-31 23 -28 -29 2
2019-12-31 2 -28 -24 2
2018-12-31 0 -31 -22 4
DB:K3P Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 -19 -23
2018-03-31 -17 -20
2017-12-31 -16 -17
2017-09-30 -14 -18
2017-06-30 -17 -17
2017-03-31 -15 -16
2016-12-31 -14 -15
2016-09-30 -14 -13
2016-06-30 -10 -13
2016-03-31 -9 -16
2015-12-31 -8 -16
2015-09-30 -8 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Kiadis Pharma's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Kiadis Pharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:K3P Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Kiadis Pharma Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:K3P Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 8.08 8.08 8.08 1.00
2022-12-31
2021-12-31
2020-12-31 -1.28 -1.20 -1.36 2.00
2019-12-31 -1.42 -1.20 -1.89 4.00
2018-12-31 -1.11 -0.90 -1.20 4.00
DB:K3P Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 -1.29
2018-03-31 -1.22
2017-12-31 -1.14
2017-09-30 -1.25
2017-06-30 -1.20
2017-03-31 -1.14
2016-12-31 -1.08
2016-09-30 -0.98
2016-06-30 -1.00
2016-03-31 -1.25
2015-12-31 -1.36
2015-09-30 -1.33

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Kiadis Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Kiadis Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Kiadis Pharma has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

K3P Past Performance

  How has Kiadis Pharma performed over the past 5 years?

  • Kiadis Pharma's last earnings update was 236 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Kiadis Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Kiadis Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Kiadis Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Kiadis Pharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Kiadis Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Kiadis Pharma Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:K3P Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 -22.59 6.02 13.04
2018-03-31 -19.81 5.46 12.13
2017-12-31 -17.04 4.91 11.22
2017-09-30 -17.78 4.64 10.66
2017-06-30 -16.87 4.23 10.29
2017-03-31 -15.83 3.71 9.25
2016-12-31 -14.79 3.20 8.21
2016-09-30 -13.35 2.80 7.15
2016-06-30 -13.35 2.51 6.82
2016-03-31 -15.97 8.42 8.44
2015-12-31 -16.46 8.29 7.72
2015-09-30 -15.15 8.03 7.47
2015-06-30 -13.85 7.76 7.23
2015-03-31 -9.35 1.60 4.74
2014-12-31 -7.81 1.48 4.69
2013-12-31 -6.89 1.44 3.55
2012-12-31 -6.67 1.35 3.62

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Kiadis Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Kiadis Pharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Kiadis Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Kiadis Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Kiadis Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

K3P Health

 How is Kiadis Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Kiadis Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Kiadis Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Kiadis Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Kiadis Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Kiadis Pharma Company Filings, last reported 9 months ago.

DB:K3P Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 25.34 31.07 41.70
2018-03-31 25.34 31.07 41.70
2017-12-31 15.86 23.39 29.91
2017-09-30 3.60 19.36 13.22
2017-06-30 3.52 16.32 10.73
2017-03-31 3.52 16.32 10.73
2016-12-31 9.44 17.16 14.56
2016-09-30
2016-06-30 16.66 15.99 23.70
2016-03-31 16.66 15.99 23.70
2015-12-31 25.65 14.88 28.67
2015-09-30 25.65 14.88 28.67
2015-06-30 1.49 13.97 2.48
2015-03-31 -0.99 13.74 3.91
2014-12-31 2.67 12.22 5.67
2013-12-31 5.36 10.41 6.48
2012-12-31 12.51 8.77 9.90
  • Kiadis Pharma's level of debt (122.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (107.1% vs 122.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Kiadis Pharma has sufficient cash runway for 2.2 years based on current free cash flow.
  • Kiadis Pharma has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 31% each year.
X
Financial health checks
We assess Kiadis Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Kiadis Pharma has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

K3P Dividends

 What is Kiadis Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Kiadis Pharma dividends.
If you bought €2,000 of Kiadis Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Kiadis Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Kiadis Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:K3P Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:K3P Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Kiadis Pharma has not reported any payouts.
  • Unable to verify if Kiadis Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Kiadis Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Kiadis Pharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Kiadis Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Kiadis Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Kiadis Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

K3P Management

 What is the CEO of Kiadis Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Arthur Lahr
COMPENSATION €934,620
AGE 50
TENURE AS CEO 2 years
CEO Bio

Mr. Arthur Lahr has been Chief Executive Officer of Kiadis Pharma N.V. since April 01, 2017 and served as its Chief Operating Officer from January 1, 2017 to April 01, 2017. Mr. Lahr served as Chief Executive Officer of FastTrack Company. Mr. Lahr served as the Head of the Protein Business Unit at Crucell N.V. since July 18, 2007 and served as its Chief Strategy Officer. Mr. Lahr served as Executive Vice President of Business Development of Crucell N.V. since January 2004 and served as its Executive Vice President of Sales. Mr. Lahr serves as Member of the Management board of Kiadis Pharma N.V. He served as Vice President of Business Development of Crucell N.V since December 2003, as Executive Vice President since January 2006 and assumed responsibility for European marketing, sales and strategy in 2006. Mr. Lahr joined Crucell N.V in April 2001 as an Executive Director of Business Development. From 1994 to 2001, he served as a Consultant of McKinsey & Co. in The Netherlands and New York. Prior to that, he worked with Unilever. He served as Member of the Governance Board at Percivia LLC. Mr. Lahr holds a Masters in Business Administration from INSEAD and a Masters in Science in Applied Physics from the University of Delft, the Netherlands.

CEO Compensation
  • Insufficient data for Arthur to compare compensation growth.
  • Arthur's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Kiadis Pharma management team in years:

0.5
Average Tenure
50
Average Age
  • The average tenure for the Kiadis Pharma management team is less than 2 years, this suggests a new team.
Management Team

Arthur Lahr

TITLE
CEO & Member of the Management Board
COMPENSATION
€935K
AGE
50
TENURE
2 yrs

Scott Holmes

TITLE
Chief Financial Officer
AGE
44
TENURE
0.3 yrs

Jan Feijen

TITLE
Chief Operating Officer
TENURE
2 yrs

Robert Friesen

TITLE
Chief Scientific Officer
TENURE
0.2 yrs

James Joy

TITLE
General Counsel & Company Secretary
TENURE
0.8 yrs

Marcel Zwaal

TITLE
Head of Corporate Development
TENURE
0.4 yrs

Mark Schaefer

TITLE
Chief Human Resources Officer
TENURE
0.6 yrs

Andrew Sandler

TITLE
Chief Medical Officer
AGE
53
TENURE
1.5 yrs

Dirk De Naeyer

TITLE
Head of Supply Chain
TENURE
0.4 yrs

Jonathan Sweeting

TITLE
Head of Commercial Europe
TENURE
0.4 yrs
Board of Directors Tenure

Average tenure and age of the Kiadis Pharma board of directors in years:

3.5
Average Tenure
56
Average Age
  • The tenure for the Kiadis Pharma board of directors is about average.
Board of Directors

Mark Wegter

TITLE
Chairman of Supervisory Board
AGE
49
TENURE
3.8 yrs

Berndt A. Modig

TITLE
Vice-Chairman of the Supervisory Board
COMPENSATION
€40K
AGE
59
TENURE
3.3 yrs

Martijn Kleijwegt

TITLE
Member of the Supervisory Board
AGE
63
TENURE
13.3 yrs

Richard Champlin

TITLE
Member of Scientific Advisory Board

Jerome Ritz

TITLE
Member of Scientific Advisory Board

Steven Devine

TITLE
Member of Scientific Advisory Board

Denis-Claude Roy

TITLE
Member of Scientific Advisory Board

Armand Keating

TITLE
Member of Scientific Advisory Board

Robert Soiffer

TITLE
Member of Supervisory Board
COMPENSATION
€40K
TENURE
2.8 yrs

Ginna Laport

TITLE
Member of Scientific Advisory Board
AGE
53
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Kiadis Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Kiadis Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

K3P News

Simply Wall St News

K3P Company Info

Description

Kiadis Pharma N.V., a clinical stage biopharmaceutical company, engages in the pharmaceutical development of cell-based immunotherapy products in the field of blood building system diseases. Its lead product candidate is ATIR101 that is in Phase III clinical trials to address key risks and limitations of hematopoietic stem cell transplantation for adult blood cancers. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands.

Details
Name: Kiadis Pharma N.V.
K3P
Exchange: DB
Founded: 1997
€244,144,342
24,341,410
Website: http://www.kiadis.com
Address: Kiadis Pharma N.V.
Paasheuvelweg 25,
Amsterdam,
Noord-Holland, 1105 BP,
Netherlands
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTAM KDS Ordinary Shares Euronext Amsterdam NL EUR 02. Jul 2015
OTCPK KIAD.F Ordinary Shares Pink Sheets LLC US USD 02. Jul 2015
DB K3P Ordinary Shares Deutsche Boerse AG DE EUR 02. Jul 2015
LSE 0RBP Ordinary Shares London Stock Exchange GB EUR 02. Jul 2015
Number of employees
Current staff
Staff numbers
68
Kiadis Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 22:54
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2018/08/31
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.